Open AccessAdoptive immunotherapy after hematopoietic stem cell transplantation
Author(s) -
Richard K. Burt,
Charles J. Link,
Ann E. Traynor
Publication year - 1998
Publication title -
current opinion in oncology/current opinion in oncology, with cancerlit
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.297
H-Index - 95
eISSN - 1080-8140
pISSN - 1040-8746
DOI - 10.1097/00001622-199811000-00009
Subject(s) - medicine , immunotherapy , adoptive immunotherapy , immunology , hematopoietic stem cell transplantation , transplantation , cell therapy , adoptive cell transfer , stem cell , immune system , t cell , biology , genetics
Adoptive immunotherapy may be performed with either autologous or allogeneic lymphocytes. Autologous cellular immunotherapy is hindered by the inability to break anergy or self-tolerance. Advances in this area have focused on the use of tumor-specific lymphocytes activated by antigen-pulsed or transgene modified dendritic cells. Allogeneic cellular immunotherapy is effective even with the use of non-specific and unactivated donor lymphocytes. Allogeneic cellular therapy is, however, complicated by graft-versus-host disease (GVHD). Advances in allogeneic immunotherapy will require better control of GVHD.